Baraolude (entecavir; Bristol-Myers Squibb) is now indicated for the treatment of paediatrio patients with chronic hepatitis B virus infection who are nucleoside naive and aged 2-18 years with compensated liver disease who have evidence of active viral replication and persistently elevated serum alanine aminotransferase levels, or histological evidence of moderate to severe inflammation and/or fibrosis. Information regarding dosing and clinical trial data in the paediatrio population has been added to the summary of product characteristics.
展开▼
